Icon: Information

Qelbree and
ADHD FAQs

Qelbree is a once-daily sprinkable capsule that treats ADHD in patients ages 6-17.1

See how it works 

The most common adverse reactions (occurring at >/= to 5% and at least twice the placebo rate for any dose) were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability.2

Adverse reactions 

Ask your patients about their medical conditions, including if they:

  • If they have or their family has a history of suicide, bipolar disorder, depression, mania or hypomania
  • Have blood pressure or heart rate problems
  • Have severe kidney disease or dysfunction. Their dose of Qelbree and/or other medicines may need to be reduced3
  • Have liver problems
  • Are pregnant or plan on becoming pregnant
  • Are breastfeeding or plan to breastfeed

Ask your patients about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking Qelbree with certain other medicines may cause side effects or affect how well they work.

Especially ask if your patients take:

  • Asthma medicines including theophylline
  • Anti-depression medicines including MAOIs (monoamine oxidase inhibitors)
  • Medicines metabolized by liver enzymes CYP1A2, 2D6 or 3A4

Do not administer Qelbree if patients are allergic to viloxazine or any of the other ingredients in Qelbree. See the end of the Medication Guide for a complete list of ingredients in Qelbree.

Do not administer Qelbree if patients also take a medicine called a monoamine oxidase inhibitor (e.g., isocarboxazid, phenelzine, selegiline, tranylcypromine).

Icon: Thermometer

Store Qelbree capsules at room temperature 77°F (25°C). Keep Qelbree and all medicines out of reach of children.1

Once-daily Qelbree shows no evidence of abuse potential or dependence across several phase III clinical trials – minimizing the risk of misuse and diversion.2,4

Adverse reactions 

Qelbree can be taken with or without food, whole or sprinkled entire contents onto a teaspoonful of applesauce and all consumed within 2 hours. Capsules and their contents should not be cut, crushed, chewed.1

See more on dosing 

Qelbree™ (viloxazine extended-release capsules) 100-mg capsule

100 mg: yellow, opaque body and cap (printed “SPN” on the cap, “100” on the body)1

Qelbree™ (viloxazine extended-release capsules) 150-mg capsule

150 mg: lavender, opaque body and cap (printed “SPN” on the cap, “150” on the body)1

Qelbree™ (viloxazine extended-release capsules) 200-mg capsule

200 mg: light green, opaque body and cap (printed “SPN” on the cap, “200” on the body)1

See inside the new chemical entity 

You might also be interested in:

Request a representative Sign up for updates 

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients ages 6 to 17.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in pediatric [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in pediatric patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more]Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

IMPORTANT SAFETY INFORMATION (CONT’D)

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability.

DOSING SAFETY INFORMATION

  • Swallow Qelbree capsules whole or sprinkle entire contents on a teaspoonful of applesauce and consume all within 2 hours, without regard to meals. Do not cut, crush, or chew the capsules
  • Severe renal impairment: Initiate Qelbree at 100 mg once daily and increase by 50 mg to 100 mg at weekly intervals to a maximum recommended dosage of 200 mg once daily
  • Prior to initiating treatment, following increases in dosage, and periodically during therapy, measure heart rate and blood pressure
  • Qelbree is a strong CYP1A2 inhibitor. Coadministration with moderately sensitive CYP1A2 substrates (eg, clozapine and pirfenidone) is not recommended. If coadministered, dose reduction may be warranted
  • Qelbree is a weak inhibitor of CYP2D6 and CYP3A4, which increases exposure of those substrates (eg, dextromethorphan and alfentanil) when coadministered with Qelbree. Monitor patients for adverse reactions and adjust dosages of substrates as clinically indicated
    • For a more complete list of drug-to-drug interactions, including clinical effects and examples, please see table 2 in section 7 of the full Prescribing Information

PREGNANCY & LACTATION

  • Qelbree may cause maternal harm. It is not known if Qelbree passes into breastmilk or if Qelbree has an effect on the breastfed infant. Discontinue Qelbree if the risks of therapy during pregnancy outweigh the benefits

Please see full Prescribing Information, including Boxed Warning.

References:

1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.
2. Data on file, Supernus Pharmaceuticals.
3. Qelbree Medication Guide, Supernus Pharmaceuticals, Inc.

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric patients ages 6 to 17.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in pediatric [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in pediatric patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more]Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

IMPORTANT SAFETY INFORMATION (CONT’D)

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability.

DOSING SAFETY INFORMATION

  • Swallow Qelbree capsules whole or sprinkle entire contents on a teaspoonful of applesauce and consume all within 2 hours, without regard to meals. Do not cut, crush, or chew the capsules
  • Severe renal impairment: Initiate Qelbree at 100 mg once daily and increase by 50 mg to 100 mg at weekly intervals to a maximum recommended dosage of 200 mg once daily
  • Prior to initiating treatment, following increases in dosage, and periodically during therapy, measure heart rate and blood pressure
  • Qelbree is a strong CYP1A2 inhibitor. Coadministration with moderately sensitive CYP1A2 substrates (eg, clozapine and pirfenidone) is not recommended. If coadministered, dose reduction may be warranted
  • Qelbree is a weak inhibitor of CYP2D6 and CYP3A4, which increases exposure of those substrates (eg, dextromethorphan and alfentanil) when coadministered with Qelbree. Monitor patients for adverse reactions and adjust dosages of substrates as clinically indicated
    • For a more complete list of drug-to-drug interactions, including clinical effects and examples, please see table 2 in section 7 of the full Prescribing Information

PREGNANCY & LACTATION

  • Qelbree may cause maternal harm. It is not known if Qelbree passes into breastmilk or if Qelbree has an effect on the breastfed infant. Discontinue Qelbree if the risks of therapy during pregnancy outweigh the benefits

Please see full Prescribing Information, including Boxed Warning.